Hepatitis C nursing reference: assessment, treatment, and patient care

LS
By Lindsay Smith, AGPCNP
Updated March 23, 2026

Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the United States, affecting an estimated 2.4 million people — the majority of whom were infected before routine screening was widely available. Unlike hepatitis B, there is no vaccine for HCV, but modern direct-acting antiviral (DAA) therapy has transformed the disease from a decades-long chronic illness into a curable condition in more than 95% of patients. For nursing students, hepatitis C is clinically significant across med-surg, infectious disease, substance use, and community health rotations — and the HCV testing sequence and treatment monitoring are recurring NCLEX topics.

This reference covers HCV from the nursing perspective: transmission and epidemiology, serologic diagnosis, pathophysiology, nursing assessment and lab values, DAA treatment with nursing pharmacology, nursing interventions, and the major complications including cirrhosis and extrahepatic manifestations. For downstream hepatic complications, pair this with the cirrhosis nursing reference and the liver failure nursing reference.

Quick reference: key HCV facts

Feature Detail
Causative agent Hepatitis C virus (HCV) — positive-sense single-stranded RNA virus, Flaviviridae family
Genotypes 7 genotypes (1–7); genotype 1 accounts for 60–70% of US infections
Primary transmission Blood-to-blood contact — primarily injection drug use (IDU); also needlestick injuries, blood transfusion pre-1992, perinatal exposure (0–4%)
Incubation period 2 weeks to 6 months (average 6–7 weeks)
Acute-to-chronic rate ~75–85% of acutely infected individuals develop chronic HCV infection
Spontaneous clearance Only 15–25% of acutely infected people clear the virus without treatment
Cirrhosis risk ~20% of chronically infected people develop cirrhosis within 20 years
HCC risk 1–5% of chronically infected people develop hepatocellular carcinoma within 30 years
Cure rate with DAAs >95% SVR12 (sustained virologic response at 12 weeks post-treatment = cure)
Vaccine available? No — HCV mutates rapidly; no protective immune response is generated

HCV serology and the testing sequence

The CDC-recommended HCV testing algorithm follows a clear two-step sequence. Understanding each step — and what each result means — is essential for safe nursing practice and is frequently tested on the NCLEX.

The four-step testing sequence

Step Test What it detects Result interpretation
1. Initial screening Anti-HCV antibody (EIA or CLIA) IgG antibody to HCV — indicates prior exposure, not necessarily active infection Reactive: proceed to HCV RNA. Non-reactive: no current infection (unless recent exposure — window period is 8–11 weeks)
2. Confirmatory / active infection HCV RNA (quantitative PCR) Viral RNA — confirms active, replicating infection Detected: active HCV infection — proceed to genotype and treatment evaluation. Undetectable: either resolved prior infection or false-positive antibody; anti-HCV remains positive for life after infection (even after cure)
3. Treatment planning HCV genotype (if RNA detected) Identifies HCV genotype 1–7 — historically guided choice of regimen; now relevant mainly for cirrhotic patients and pangenotypic drug selection Genotype 1 most common in US; most modern DAA regimens are pangenotypic and active against all genotypes
4. Cure confirmation HCV RNA at 12 weeks post-treatment (SVR12) Confirms viral eradication — HCV RNA undetectable at 12 weeks after completing DAA therapy = sustained virologic response = cure Undetectable at SVR12: cured — no need to repeat anti-HCV (antibodies persist lifelong even after cure and are not an indicator of active infection). Detectable: treatment failure or reinfection — refer back to hepatology

Key nursing points on serology:

  • Anti-HCV is a screening test, not a diagnosis. A reactive anti-HCV must be followed by HCV RNA before any clinical conclusions are drawn.
  • Anti-HCV antibodies persist for life regardless of whether infection resolved spontaneously or was cured with treatment. A positive anti-HCV in a treated patient does not mean active infection — you must check HCV RNA.
  • The window period for anti-HCV is approximately 8–11 weeks. A patient with a recent high-risk exposure and a negative anti-HCV should be retested in 3–6 months.
  • HCV RNA becomes detectable within 1–2 weeks of exposure — before antibodies appear. In a high-suspicion acute exposure, HCV RNA is the appropriate initial test.

HCV genotypes

HCV has seven genotypes (1–7) with distinct geographic distributions. Genotype identification matters for a subset of clinical decisions — particularly in cirrhotic patients and for resistance testing in genotype 3.

Genotype Prevalence in US Geographic concentration Clinical notes
1 60–70% North America, Europe, worldwide Most common in US; historically hardest to treat with interferon; responds well to modern pangenotypic DAAs
2 ~15% Europe, North America High response rates to all DAA regimens
3 ~10% South Asia, Europe Associated with higher risk of steatosis and accelerated fibrosis; genotype 3 with cirrhosis requires resistance testing (Y93H mutation check) before sofosbuvir/velpatasvir
4 <5% Middle East, North Africa Responds well to pangenotypic DAAs
5, 6, 7 Rare in US South Africa, Southeast Asia, Central Africa Pangenotypic DAAs active against these genotypes

The clinical bottom line: For most treatment-naive patients without cirrhosis, genotype testing is no longer required before starting therapy — pangenotypic DAA regimens work across all genotypes. Genotype testing remains relevant for patients with cirrhosis (especially genotype 3) and for complex treatment decisions.

Transmission and epidemiology

HCV is transmitted through direct blood-to-blood contact. It is far less efficiently transmitted through sexual contact than HBV, and casual contact does not transmit HCV.

Primary transmission routes:

  • Injection drug use (IDU): The dominant route in the US — sharing needles, syringes, or other drug preparation equipment. IDU accounts for approximately 60% of new HCV infections.
  • Blood transfusion or organ transplant before 1992: Before blood supply screening was implemented in 1992, transfusions were a significant source of HCV infection. Patients who received blood products before 1992 are at elevated risk and should be screened.
  • Needlestick injury and occupational exposure: Healthcare workers face risk from percutaneous exposures to HCV-positive blood; estimated transmission rate per needlestick is approximately 1.8%.
  • Perinatal transmission: Mother-to-infant transmission during childbirth; occurs in approximately 0–4% of births to HCV RNA-positive mothers. Risk is higher with HCV/HIV coinfection.
  • Hemodialysis: Patients on long-term hemodialysis are at elevated risk due to shared equipment or lapses in infection control.
  • Tattooing and body piercing: Non-sterile equipment; risk is lower with licensed, regulated facilities.
  • Sexual transmission: Rare in monogamous heterosexual relationships but elevated with multiple partners, concurrent STIs, or practices that involve blood exposure.

HCV is not transmitted through: hugging, kissing, sharing food or drinks, coughing, sneezing, or breastfeeding (absent bleeding nipples or cracked skin).

Who to screen: The CDC and USPSTF recommend HCV screening for all adults aged 18–79 at least once, all pregnant women during each pregnancy, and anyone with ongoing risk factors (IDU, incarceration, long-term hemodialysis, healthcare workers after exposure).

Pathophysiology

Acute HCV infection

After blood-to-blood exposure, HCV enters the bloodstream and infects hepatocytes. Unlike HBV — which is a DNA virus — HCV is an RNA virus that replicates entirely within the cytoplasm using an NS5B RNA-dependent RNA polymerase. This replication mechanism generates an exceptionally high viral mutation rate (approximately 10 trillion new viral particles per day in chronic infection), explaining both the development of multiple genotypes and quasi-species and HCV’s ability to evade immune clearance.

The incubation period ranges from 2 weeks to 6 months, with an average of 6–7 weeks. Most people with acute HCV infection — approximately 70–80% — are asymptomatic or have only mild, nonspecific symptoms. When symptoms do occur, they resemble acute hepatitis from other causes: fatigue, malaise, nausea, right upper quadrant discomfort, and occasionally jaundice. Fulminant hepatic failure from acute HCV is rare.

Only 15–25% of people infected with HCV mount an effective immune response and clear the virus spontaneously. Factors favoring spontaneous clearance include female sex, younger age at infection, and certain host immune genetics (IL28B CC genotype). The immune mechanisms that drive clearance versus chronicity are not fully understood.

Chronic HCV infection

The 75–85% who do not clear acute HCV develop chronic infection, defined as detectable HCV RNA beyond 6 months. Unlike HBV, where the damage is largely immune-mediated, HCV is also mildly cytopathic — the virus itself causes some direct hepatocyte injury, while the host immune response drives additional inflammation.

In chronic infection, HCV triggers hepatic stellate cell activation, leading to progressive collagen deposition and fibrosis. Over years to decades, this fibrosis advances through stages (typically scored by the METAVIR system: F0 = no fibrosis → F4 = cirrhosis). Approximately 20% of chronically infected people develop cirrhosis within 20 years, and 1–5% develop hepatocellular carcinoma within 30 years. Factors that accelerate fibrosis progression include:

  • Alcohol use (even moderate consumption significantly accelerates fibrosis)
  • HIV or HBV coinfection
  • Male sex
  • Older age at infection
  • Insulin resistance and hepatic steatosis (especially in genotype 3)
  • Immunosuppression

Nursing assessment

History and risk factor screening

When assessing a patient with known or suspected HCV:

  • Injection drug use: Past or current — even a single exposure decades ago. Many patients are reluctant to disclose; approach without judgment.
  • Blood transfusion or organ transplant before 1992
  • Long-term hemodialysis history
  • Tattoos or piercings from non-sterile settings
  • Incarceration history (elevated HCV prevalence in correctional facilities)
  • Healthcare occupation with needlestick or blood exposure history
  • Sexual history — multiple partners, prior STIs
  • Perinatal exposure — born to an HCV-positive mother
  • Alcohol and substance use — critical for fibrosis risk stratification and treatment readiness
  • Current medications and supplements — many have significant drug-drug interactions with DAAs

Physical assessment

Most patients with chronic HCV are asymptomatic until cirrhosis develops. When findings are present:

  • Vital signs: Fever may indicate superimposed infection in advanced liver disease
  • Abdomen: Hepatomegaly, right upper quadrant tenderness; assess for ascites (fluid wave, shifting dullness); splenomegaly suggests portal hypertension
  • Skin and sclera: Jaundice (scleral icterus first), spider angiomas, palmar erythema, ecchymoses; in cryoglobulinemia: palpable purpura on lower extremities
  • Neurological: Confusion, asterixis (flapping tremor) — signs of hepatic encephalopathy in advanced disease
  • Musculoskeletal: Arthralgias in extrahepatic manifestations
  • Renal: Peripheral edema, frothy urine — cryoglobulinemic nephropathy

Lab monitoring

Lab Finding in HCV Clinical significance
ALT (SGPT) Elevated — may fluctuate; can be normal in chronic HCV even with active disease Most specific marker of hepatocyte injury; ALT > AST in viral hepatitis. Importantly, normal ALT does not rule out significant fibrosis.
AST (SGOT) Elevated; AST:ALT >2:1 suggests alcohol contribution or advanced cirrhosis Less liver-specific than ALT; also found in heart and muscle. AST:ALT ratio shifts as cirrhosis worsens.
HCV RNA (viral load) Detectable — quantified in IU/mL Confirms active infection; used at baseline and at SVR12 to confirm cure. Level does not correlate with disease severity.
FIB-4 score Calculated from age, AST, ALT, and platelet count Non-invasive fibrosis estimate. FIB-4 <1.30 = low fibrosis risk; FIB-4 >3.25 = likely advanced fibrosis/cirrhosis (presumed cirrhosis for treatment purposes). Replaces liver biopsy in most cases.
Platelet count Low in advanced disease (thrombocytopenia) Hypersplenism from portal hypertension; used in FIB-4 calculation; falling platelets signal advancing fibrosis.
Albumin Normal in early disease; low in advanced cirrhosis Marker of hepatic synthetic function — hypoalbuminemia signals decompensating disease.
PT/INR Prolonged in moderate-to-severe disease Liver synthesizes coagulation factors II, VII, IX, X; prolonged INR signals failing synthetic function and bleeding risk.
Total bilirubin Elevated in jaundice or significant hepatic dysfunction Jaundice visible when total bilirubin exceeds ~3 mg/dL; rising bilirubin signals worsening liver function.
Anti-HCV antibody Reactive (positive) Confirms prior exposure only — not active infection. Remains positive for life even after spontaneous clearance or successful DAA treatment.
HBsAg, anti-HIV Checked at baseline before DAA treatment HBV/HIV coinfection requires coordinated management; HBV reactivation can occur with DAA initiation. AASLD guidelines require HBV screening before starting DAAs.

For the full lab interpretation framework, see the nursing lab values cheat sheet.

FIB-4 score calculation: FIB-4 = (Age × AST) ÷ (Platelet count [10⁹/L] × √ALT). This calculation is embedded in most EHR systems; nursing students should know what it estimates (degree of hepatic fibrosis) and its clinical thresholds.

Priority assessment findings requiring immediate escalation

Call the provider immediately for:

  • Altered mental status, confusion, or asterixis in a patient with liver disease — hepatic encephalopathy until proven otherwise
  • GI bleeding: hematemesis, melena, or bright red blood per rectum — variceal hemorrhage is life-threatening
  • INR trending up rapidly in acute hepatitis — fulminant failure
  • Hypotension with jaundice or ascites
  • Hypoglycemia — hepatic gluconeogenesis failing
  • Sudden worsening of renal function (creatinine rising) in a cirrhotic patient — hepatorenal syndrome

Treatment: direct-acting antivirals (DAAs)

Modern DAA therapy has transformed hepatitis C management. Where interferon-based regimens cured 40–50% of patients with 24–48 weeks of difficult, side-effect-laden treatment, current pangenotypic DAA regimens cure more than 95% of patients in 8–12 weeks with minimal side effects.

Mechanism of action

DAAs target specific viral proteins required for HCV replication:

  • NS5A inhibitors (e.g., velpatasvir, pibrentasvir): Block the NS5A protein, which is essential for viral RNA replication and assembly
  • NS5B inhibitors (e.g., sofosbuvir): Block the NS5B RNA-dependent RNA polymerase — the enzyme that copies HCV’s genome
  • NS3/4A protease inhibitors (e.g., glecaprevir): Block viral polyprotein processing

The most widely used pangenotypic regimens combine inhibitors from multiple classes to prevent resistance.

First-line pangenotypic DAA regimens

Regimen Drugs / Brand Duration (no cirrhosis) Duration (compensated cirrhosis) SVR12 rate Nursing notes
Sofosbuvir/velpatasvir Epclusa — NS5B + NS5A inhibitor; one tablet daily 12 weeks 12 weeks (resistance testing required for GT3 with cirrhosis — avoid if Y93H mutation) ~99% Take with or without food; check drug interactions; monitor HCV RNA at SVR12. Avoid with strong CYP inducers (rifampin, carbamazepine).
Glecaprevir/pibrentasvir Mavyret — NS3/4A + NS5A inhibitor; three tablets daily 8 weeks 8 weeks (compensated cirrhosis only) >99% Take with food (required for absorption); shorter duration makes it favorable for adherence concerns. Contraindicated in decompensated cirrhosis (Child-Pugh B or C) — protease inhibitors can worsen hepatic decompensation.

Important nursing pharmacology points:

  • Hepatitis B reactivation: Patients with HBsAg positivity or anti-HBc positivity are at risk for HBV reactivation when starting DAA therapy (mechanism not fully understood — possibly immune reconstitution). Screen for HBV before starting DAAs; manage coinfection with hepatology.
  • Drug-drug interactions: Both regimens have significant interactions. Key ones for nursing to know: antacids (separate from glecaprevir/pibrentasvir by 3 hours), strong CYP inducers (rifampin, phenytoin, carbamazepine contraindicated with most DAAs), amiodarone + sofosbuvir combinations (risk of severe bradycardia).
  • Diabetes monitoring: DAA treatment improves glycemic control as liver function improves — monitor blood glucose in diabetic patients; insulin or oral hypoglycemic doses may need adjustment.
  • Warfarin monitoring: Improving liver function during DAA therapy can increase coagulation factor synthesis, altering INR in patients on warfarin — monitor INR more frequently.
  • SVR12 is the endpoint: Remind patients that the HCV RNA test at 12 weeks after completing treatment confirms cure. If they feel well and stop taking pills early, cure may not be achieved.
  • Reinfection is possible: SVR12 means cure from that episode of infection, not lifelong immunity. Patients with ongoing risk behaviors (active IDU) can be reinfected; counsel on harm reduction and offer annual HCV RNA testing if risk factors persist.

Decompensated cirrhosis

Glecaprevir/pibrentasvir is contraindicated in decompensated cirrhosis (Child-Pugh B or C) due to the NS3/4A protease inhibitor component. Sofosbuvir/velpatasvir is the preferred option in decompensated cirrhosis, often in combination with ribavirin; these patients require specialist hepatology management. See the liver failure nursing reference for decompensated cirrhosis management.

Nursing interventions

Monitoring

  • Assess vital signs, fluid balance, and daily weight — fluid retention (ascites, peripheral edema) signals advancing portal hypertension
  • Monitor LFTs, INR, albumin, and bilirubin; document trends and report worsening values
  • Check platelet count and calculate FIB-4 to track fibrosis stage
  • Monitor for signs of GI bleeding: hematemesis, melena, change in stool color, tachycardia, hypotension
  • Assess neurological status: orientation, asterixis — hepatic encephalopathy can emerge with any acute decompensation
  • During DAA treatment: no routine lab monitoring needed for noncirrhotic patients; monitor LFTs and assess for adverse effects in cirrhotic patients

Infection control

HCV is a blood-borne pathogen. Apply standard precautions for all patients. Contact precautions are not required beyond standard precautions unless there is active bleeding or wound drainage.

For healthcare workers:

  • Standard precautions are the primary protection — there is no post-exposure prophylaxis for HCV (unlike HBV or HIV) and no vaccine
  • Report all needlestick and blood exposures immediately; baseline HCV RNA should be obtained and the patient source tested; follow-up testing is recommended at 6 weeks (HCV RNA) and 6 months (anti-HCV)
  • Use safety-engineered sharps devices and needleless IV systems
  • If HCV transmission is confirmed after a needlestick, early DAA treatment (within weeks of acute infection) achieves very high cure rates — notify occupational health promptly

Harm reduction and screening support

For patients who inject drugs:

  • Non-judgmental assessment: IDU patients often delay seeking care due to stigma from healthcare providers; a non-judgmental approach improves screening and treatment uptake
  • Connect with syringe service programs (needle exchange) — reduces HCV transmission risk
  • Offer medication-assisted treatment (MAT) referral if patient is interested — patients on stable MAT (methadone, buprenorphine) are appropriate candidates for DAA therapy
  • Counsel that reinfection is possible after SVR12 — harm reduction is ongoing

Comfort and symptom management

  • Fatigue: The most common complaint in chronic HCV; cluster nursing care to allow rest periods; validate that fatigue is a genuine symptom, not malingering
  • Pruritus: Cool baths, loose cotton clothing, emollients; report severe pruritus — cholestyramine may be prescribed if bile salt-related
  • Nausea: Small frequent meals; offer bland easily digested foods; administer antiemetics as prescribed
  • Arthralgias: Warm compresses, positioning; NSAIDs should be avoided in patients with significant liver disease (renal and GI bleeding risks); acetaminophen can be used cautiously (avoid >2 g/day total in liver disease)

Patient education priorities

  1. What SVR12 means: Completing treatment and testing HCV RNA-negative 12 weeks later = cured. The anti-HCV antibody will remain positive for life — this is expected and does not mean the virus is still present.
  2. Alcohol avoidance: Alcohol dramatically accelerates hepatic fibrosis and counteracts the benefit of DAA treatment. Complete abstinence is the goal.
  3. Transmission prevention: Do not share needles, syringes, glucose monitoring equipment, razors, nail clippers, or toothbrushes. Cover open wounds. Sexual transmission is low but possible — disclose status to partners and use barrier protection if risk factors are present.
  4. Medication adherence: DAA treatment must be completed; stopping early risks treatment failure. If a dose is missed, take it as soon as remembered — if close to the next dose, skip the missed dose and continue.
  5. Drug interactions: Patients must tell all providers (including dentists and pharmacists) that they are on DAA therapy before starting any new medication.
  6. Post-SVR follow-up for cirrhotic patients: SVR12 does not eliminate HCC risk in patients who have already developed cirrhosis — ultrasound surveillance every 6 months continues regardless of cure. Non-cirrhotic patients achieving SVR require no further liver-specific follow-up.
  7. HBV vaccination: HBV/HCV coinfection accelerates liver disease; HCV-infected patients who are not immune to HBV should be vaccinated.
  8. Notify partners and household contacts: Sexual partners should be screened; household members who may have shared sharp objects should be tested.

Complications

Cirrhosis

Approximately 20% of chronically infected individuals develop cirrhosis within 20 years. As fibrosis advances to cirrhosis (METAVIR F4), portal hypertension develops, leading to the classic complications: ascites, esophageal and gastric varices, hepatic encephalopathy, and spontaneous bacterial peritonitis. The transition from compensated to decompensated cirrhosis marks a dramatic change in prognosis — median survival without transplantation is approximately 2 years after decompensation. See the cirrhosis nursing reference for comprehensive management.

Important distinction from HBV: In hepatitis B, HCC can develop even without cirrhosis. In hepatitis C, HCC almost always arises on a background of cirrhosis or advanced fibrosis. This distinction is NCLEX-tested.

Hepatocellular carcinoma (HCC)

HCV is a leading cause of HCC in the United States, responsible for approximately 50% of cases. HCC risk is highest in patients with established cirrhosis (especially Child-Pugh B or C). Even after achieving SVR12, cirrhotic patients retain elevated HCC risk — HCC surveillance with liver ultrasound (with or without AFP) every 6 months continues indefinitely. Non-cirrhotic patients who achieve SVR are not routinely surveilled.

Cryoglobulinemia

Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. Cryoglobulins — immunoglobulins that precipitate at low temperatures — are detected in approximately 50% of patients with chronic HCV, though only 25–30% develop symptomatic cryoglobulinemia. The pathophysiology is immune complex-mediated: HCV-driven B-cell activation produces cryoglobulins that deposit in small blood vessels.

Clinical presentation of HCV-associated cryoglobulinemia:

  • Purpura: Palpable purpura on the lower extremities — the hallmark finding; may range from petechiae to large ecchymotic patches
  • Arthralgias: Symmetric joint pain, commonly involving the knees, ankles, and wrists
  • Peripheral neuropathy: Sensory deficits, paresthesias, or burning pain — axonal polyneuropathy from vasculitic nerve involvement
  • Renal disease: Membranoproliferative glomerulonephritis — presents with proteinuria, hematuria, hypertension, and declining renal function; can progress to renal failure
  • Raynaud’s phenomenon: Vasospasm of digital arteries on cold exposure
  • Fatigue and weakness: Present in most symptomatic patients

Nursing assessment for cryoglobulinemia: inspect lower extremities for purpura; assess for peripheral sensory changes; monitor urine for protein and blood; check blood pressure; ask about joint pain and cold sensitivity.

DAA treatment is the first-line management for HCV-associated cryoglobulinemia — achieving SVR12 leads to resolution of cryoglobulinemia in most patients.

Other extrahepatic manifestations

Beyond cryoglobulinemia, chronic HCV is associated with a spectrum of extrahepatic conditions driven by HCV-triggered immune dysregulation:

  • B-cell non-Hodgkin lymphoma: HCV-driven B-cell proliferation; HCV-infected patients have a 2–3-fold increased risk of B-cell NHL compared to the general population
  • Porphyria cutanea tarda (PCT): Photosensitive blistering skin lesions on sun-exposed areas; caused by HCV-related iron overload impairing uroporphyrinogen decarboxylase
  • Lichen planus: Flat-topped, pruritic, violaceous papules on skin and oral mucosa; associated with HCV infection
  • Type 2 diabetes: Chronic HCV promotes insulin resistance through direct viral effects on hepatic glucose metabolism; patients with HCV have a higher prevalence of type 2 diabetes
  • Thyroid disease: HCV is associated with increased risk of thyroid autoimmunity and hypothyroidism — check TSH in symptomatic patients

This reference is part of the hepatic sub-pillar. For related content, see: